Free tool
FAERS Monitor: Linzess
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 202811 or its brand name (Linzess, Linaclotide). Reports on generic versions are filed under their own applications.
Reports
27,305
Serious
9,962
36% of reports
Hospitalization
4,080
Death reported
1,100
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea4,777
- drug ineffective4,586
- off label use3,406
- constipation2,071
- nausea1,522
- fatigue1,213
- abdominal distension1,188
- abdominal pain1,089
- headache1,073
- pain991
- abdominal pain upper969
- dizziness879
- inappropriate schedule of product administration787
- fall743
- flatulence721
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 9 |
| 2013 | 597 |
| 2014 | 1,295 |
| 2015 | 1,290 |
| 2016 | 2,129 |
| 2017 | 2,256 |
| 2018 | 2,579 |
| 2019 | 2,374 |
| 2020 | 2,225 |
| 2021 | 1,937 |
| 2022 | 1,882 |
| 2023 | 1,994 |
| 2024 | 2,049 |
| 2025 | 2,478 |
| 2026 | 2,211 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,026,854 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| flatulenceSignal | 721 | 9.9 | 9.2 | 5,706 |
| abdominal distensionSignal | 1,188 | 8.9 | 8.4 | 8,218 |
| constipationSignal | 2,071 | 7.4 | 7.1 | 11,417 |
| diarrhoeaSignal | 4,777 | 5.7 | 5.6 | 19,122 |
| abdominal pain upperSignal | 969 | 3.6 | 3.4 | 1,860 |
| abdominal painSignal | 1,089 | 3.6 | 3.4 | 2,074 |
| inappropriate schedule of product administrationSignal | 787 | 3.4 | 3.1 | 1,318 |
| off label useSignal | 3,406 | 3.0 | 2.9 | 4,731 |
| drug ineffectiveSignal | 4,586 | 2.7 | 2.6 | 5,159 |
| fall | 743 | 1.7 | 1.6 | 227 |
| nausea | 1,522 | 1.5 | 1.4 | 247 |
| dizziness | 879 | 1.4 | 1.3 | 85 |
| headache | 1,073 | 1.3 | 1.2 | 85 |
| pain | 991 | 1.2 | 1.2 | 48 |
| fatigue | 1,213 | 1.2 | 1.1 | 42 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.